Abstract
Purpose
Type 1 Diabetes (T1D) is a T cell-mediated disease, in which autoimmune destruction of insulin-producing β-cells in pancreatic islets occurs. In recent decades, the role of Killer cell immunoglobulin-like receptor (KIR) gene polymorphisms in susceptibility to T1D has been demonstrated in an increased number of studies. Nonetheless, inconsistency has been observed in the results of performed association studies. To comprehensively clarify the association among KIR gene polymorphisms and the risk of T1D, this meta-analysis on the previously published association studies was carried out via incorporating multiple research.
Methods
No publication has been recorded from Nov 2017 until July 2020 about the KIR genes and T1D. The PubMed/MEDLINE and Scopus databases were systematically searched up to November 2017 to identify investigations on the impact of the polymorphisms of KIR genes on susceptibility to T1D. The odds ratio (OR) with a 95% confidence interval (95% CI) was calculated. Funnel plot and Egger test were used to assess the publication bias. Thirteen qualified published case-control articles were found for evaluation in this meta-analysis.
Results
Our results show statistical significance between the genetic variations in the KIR2DL1 (OR = 0.42, 95% CI = 0.23–0.77; P = 0.005), KIR2DL2 (OR = 1.15, 95% CI = 1.00-1.32; P = 0.048), and KIR2DL5 (OR = 0.86, 95% CI = 0.75–0.98; P = 0.03) with susceptibility to T1D.
Conclusions
This meta-analysis study provides reliable evidence that KIR gene polymorphisms may contribute to T1D risk. KIR 2DL1 and 2DL5 genes might be considered as a protective factor for T1D, while 2DL2 seemed to be a susceptibility factor.
Keywords
Killer cell immunoglobulin-like receptors, Natural killer cells, Meta-analysis, Polymorphism, Type 1 diabetes
Introduction
Type 1 diabetes (T1D), once known as autoimmune insulin-dependent diabetes mellitus (IDDM), is a multifactorial and polygenetic T lymphocyte-driven autoimmune disorder, in which insulin-producing (beta)- cells are attacked by the auto-immune responses and diabetes occurs [1]. Despite the fact that autoimmune diseases are primarily due to inappropriate activation of B and T cells, Natural killer (NK) cells also have been implicated to have crucial roles in such diseases processes [2].
Human NK cells and a category of T cells express various activating and inhibitory killer cell immunoglobulin-like receptors (KIRs, also known as CD158), which modulate NK and T lymphocyte functions via ligation with their given human histocompatibility leukocyte antigen class I (HLA-I) ligands on target cells [3]. The role and specific function of NK cells are managed by an accurate balance between inhibitory and activating signals. These signals stem from the interaction of corresponding cell surface KIRs with their defined HLA class I- ligands expressing on target cells [3]. For example, inhibitory KIR2DL2/2DL3 interface with HLA-C1, and inhibitory 2DL1 interacts with HLA-C2 ligands [4]. On the other hand, stimulatory 2DS1 binds to HLA-C2, and stimulatory 2DS2 combined with HLA-C1 [5]. Concerning the pathogenesis of T1D, co-stimulation by activating KIRs, alongside with dysregulation of autoreactive-cell through inhibitory KIRs, may lead to the activation of these cells and break down of tolerance for islet self-antigens [6].
In humans, KIRs, which belong to the immunoglobulin superfamily, is encoded by 17 different genes sized approximately 150-kb, located at 19q13.4 region, including KIR2DL1-4, KIR2DL5A-5B, KIR2DS1-5, KIR3DL1-3, KIR3DS1, and two pseudogenes (KIR2DP1 and 3DP1). Among them, six KIRs, including KIR2DS1-5, and 3DS1, which have a short cytoplasmic tail, are considered as activating KIRs. Nine KIRs, including KIR2DL1-4, 2DL5A, 2DL5B, and 3DL1-3, are inhibitory KIRs, which have long tails [7]. The KIR gene structure is flanked by KIR3DL3 and KIR3DL2 at the centromeric and at the telomeric end respectively, both of them exist on virtually all haplotypes [5].
There is a diversity in KIR genes content among populations [8]. Association of KIR gene polymorphisms was identified in several autoimmune diseases, such as psoriatic arthritis [9], psoriasis [10], rheumatoid arthritis [11], scleroderma [12], endometriosis [13], primary sclerosing cholangitis [14], Behcet’s disease [15], and systemic lupus erythematosus [16]. Also, several studies have reflected an association between the KIR genes and infectious diseases [17, 18], cancer [19, 20], and disorders of the reproductive system [21, 22]. Furthermore, the KIR molecules/genes have been established to be an essential risk factor for susceptibility to T1D [6, 23, 24].
Genetic screening was considered a logical first step to detect T1D affected patients to achieve a cure or, better yet, to find prevention strategies. In recent years, ample evidence supports the critical role of KIR genes in autoimmune diseases. Here, thirteen genetic studies demonstrated the association between different KIR gene polymorphisms and the individual’s predisposition to T1D, however, the findings are not consistent and conclusive. This is likely due to low statistical power, insufficient sample sizes, diverse study populations of different ethnicities, and the level of linkage disequilibrium among genotypes. Therefore, it is noteworthy that these studies require further analysis to achieve conclusive comprehension about the role of KIR allelic distribution on T1D proneness.
Meta-analyses are useful tools for outline studies on the same topics and exploring their relationship in a comprehensive way [25]. These studies increase the sample size, which may resolve the issue of lack of power, implying to the significant benefit of meta-analysis studies. The present meta-analysis of polymorphisms of KIR genes was conducted to estimate the association of KIR genes variants with T1D incidence and susceptibility.
Overall, the current meta-analysis aimed to perform universal research about the association of KIR gene variants and the risk of T1D in various populations to conclude the results of studies.
Methods
and evidence acquisition
Data sources and searches
The current study is a meta-analysis, which almost employs all the original investigations on this subject done before. We carried out a systematic search for studies that investigated the associations between polymorphisms of KIR genes and the risk of T1D. The electronic resource databases, including PubMed/MEDLINE and Scopus, were searched for all English-written articles published up to November 2017 using a combination of the following keywords: (“KIR” OR “Killer cell immunoglobulin-like receptor”) AND (“T1D” OR “Type 1 diabetes” “OR Type 1 diabetes mellitus”) with “OR” and “AND” Boolean Operators in the Title, Abstract, and Keywords fields. As I mentioned above, it is suggested to be July 2020. Moreover, to detect studies not indexed by the electronic databases, all references mentioned in identified papers were cross-checked. Thirteen papers were found.
Inclusion and exclusion criteria
Articles were selected for the analysis meeting the following criteria: (i) The study profile was case-control studies. (ii) Studies in the context of the association between KIRs gene polymorphism and T1D development. (iii) The data was original (independent among studies). (iv) Studies provided frequencies to compute odds ratio (OR) with a 95% confidence interval (CI). (v) Patients with T1D diagnosed based on the classification criteria were included in the studies. We excluded the following: (i) Studies that possessed duplication or overlapping data. (ii) The conference, letter, review, commentaries, guidelines, or abstract without a full text. (iii) Studies with insufficient data concerning KIRs gene polymorphism frequency (Fig. 1).
Data extraction and quality assessment
Data were obtained and extracted according to the mentioned criteria. The following data were extracted from each study: first author’s last name, publication year, country of origin, the ethnicity of the study population, numbers of cases and healthy controls, KIR gene typing protocol, and genotype frequency data on the KIR gene polymorphisms. The Newcastle-Ottawa Scale (NOS) was performed for evaluating the methodological quality [26]. Included studies were graded as a low, moderate, or high quality according to the following scores, 0–3, 4–6, or 7–9, respectively. Two independent investigators examined the included studies based on the criteria mentioned above to resolve any discrepancies, blindly.
Statistical methods
We used pooled odds ratio (OR) and their corresponding 95% CI for KIR alleles to evaluate gene polymorphisms and risk of T1D. For calculating phenotypic frequency (pf %) in each group, using percentage of positive numbers between all samples, genotypic frequency (gf) among all subjects was calculated (the gf = 1– (1 – pf) ½). Cochran’s Q test was applied to test the heterogeneity and I-squared index were employed for calculating the heterogeneity of odds ratios between included studies. For the heterogeneity test, the significant result was considered at P < 0.1 level [27]. When the heterogeneity between the included studies was statistically significant, the meta-analysis was performed by the random-effects model. Otherwise, the fixed-effects model was used.
Meanwhile, via successively removing a particular study that had the highest effect on the results of heterogeneity, a sensitivity analysis was performed. The funnel plot, as a method for checking publication bias, was used. Egger’s linear regression test and Begg’s test (P < 0.05 levels was considered statistically significance level of publication bias test) were used to measuring funnel plot asymmetry and testing publication bias [28]. All statistical analyses were performed using STATA (version 11.0; Stata Corporation, College Station, TX) and MedCalc software (version 12.7.2.0; Ostend, Belgium).
Results
Characteristics of the eligible studies
We obtained 125 initial items from PubMed/MEDLINE and Scopus using searching terms. One study excluded because investigated on frequencies of KIR gene polymorphism on coexisting celiac disease (CD) and T1D [29]. Another study was identified as ineligible and excluded because it was not written in English [30]. Eventually, 13 relevant studies with 2285 cases and 2118 controls in total met the inclusion requirements. Among these 13, seven were European [6, 23, 31–35], five were Asian studies [1, 3, 36–38], and one was from Brazil [39]. These studies were published in English between 2003 and 2016 (Table 1). Two types of polymerase chain reaction (PCR), including sequence-specific primer (SSP)-PCR, and sequence-specific oligonucleotide probe (SSOP)-PCR were the main detection methods used by studies in the present meta-analysis. Sixteen KIR gene variants were addressed in the mentioned studies, including KIR2DL1-5, 3DL1-3, 2DS1-5, 3DS1, 2DP1, and 3DP1. The screening process of the current study with respect to the meta-analysis of the KIR polymorphisms association with T1D susceptibility was summarized in Fig. 1. All included research had a score ranging from 7 to 9 (based on the NOS tool).
Table 1.
| No. | Author (Ref) | Published Year | Race/Country | Detection Technique | T1D Patients | Controls | KIR gene Polymorphisms |
|---|---|---|---|---|---|---|---|
| 1 | van der Slik et al. [6] | 2003 | Caucasian /Netherlands | PCR–SSOP | 149 | 207 | 2DL1, 2DL2, 2DL3, 2DL5, 3DL1, 2DS1-5, 3DS1 |
| 2 | Nikitina-Zake et al. [31] | 2004 | Caucasian/Latvia | PCR-SSP | 95 | 98 | 2DL1-5, 3DL1-3, 2DS1-5, 3DS1 |
| 3 | Middleton et al. [23] | 2006 | Caucasian/ United Kingdom | PCR | 137 | 101 | 2DL1-5, 3DL1-3, 2DS1-5, |
| 4 | Park et al.[36] | 2006 | Asian/ Korea | PCR-SSP | 138 | 132 | 2DL1-5, 3DL1-3, 3DS1, 2DS1-5 |
| 5 | Santin et al. [32] | 2006 | Caucasian/ Spain | PCR-SSP | 76 | 71 | 2DL1, 2DL2, 2DL3, 2DL5, 2DS1-5, 3DL1, 3DS1, 3DP1, 2DP1 |
| 6 | Mogami et al. [1] | 2007 | Asian/ Japan | PCR-SSP | 204 | 240 | 2DL1-5, 2DS1-5, 3DL1-3, 3DS1 |
| 7 | van der Slik et al. [33] | 2007 | Caucasian /Netherlands | Not provided | 275 | 215 | 2DS1, 2DS2, 3DS1 |
| 8 | Jobim et al. [39] | 2010 | Caucasian/ Brazil | PCR-SSP | 250 | 248 | 2DL1-5, 3DL1-3, 2DS1-5, 2DS1-5, 3DS1, 2DP1 |
| 9 | Mehers et al. [34] | 2011 | Caucasian/ United Kingdom | PCR-SSP | 394 | 168 | 2DL1, 2DL2, 2DL3, 2DL5, 3DL1, 3DL3, 2DS1-5, 3DS1 |
| 10 | Zhi et al. [3] | 2011 | Asian/ China | PCR-SSP | 259 | 262 | 2DL1, 2DL2, 2DL3, 2DL5, 2DS1-5, 3DL1, 3DS1 |
| 11 | Smigoc Schweiger et al. [35] | 2014 | Caucasian/ Slovenia | PCR-SSP | 67 | 130 | 2DL1-4, 2DL5A, 2DL5B, 2DP1, 2DS1-5, 3DL1-3, 3DP1, 3DS1 |
| 12 | Sanjeevi et al. [37] | 2015 | Asian/ India | PCR-SSP | 135 | 98 | 2DL1-5, 3DS1, 2DS1-5, 3DL1-3 |
| 13 | Osman et al. [38] | 2016 | Asian/ Saudi Arabia | PCR-SSOP | 106 | 148 | 2DL1-5, 2DS1-5, 3DL1-3, 3DS1, 2DP1, 3DP1 |
KIR; Killer cell immunoglobulin-like receptor, T1D; Type 1 diabetes, PCR; Polymerase chain reaction, PCR-SSP; Polymerase chain reaction- sequence specific primers, SSOP-PCR; sequence-specific oligonucleotide probes- polymerase chain reaction
Meta-analysis results
Meta-analysis results demonstrated three alleles with significant association, including KIR2DL1 (OR = 0.42, 95% CI = 0.23–0.77; P = 0.005), KIR2DL2 (OR = 1.15, 95% CI = 1.00-1.32; P = 0.048), and KIR2DL5 (OR = 0.86, 95% CI = 0.75–0.98; P = 0.033) with susceptibility to T1D. However, no statistically significant association was detected between 2DL3, 2DL4, 3DL1–3, 2DS1–5, 3DS1, and 3DP1 and susceptibility to T1D. Details of the allele frequency of KIR gene polymorphisms, pooled ORs, results of heterogeneity test, and publication bias tests are presented in Table 2.
Table 2.
| Polymorphism | No. of studies | T1D case n/N | Control n/N | P-value | Pooled OR (95% C.I) |
Heterogeneity Test (I2 %, P-value) |
Publication Bias (Begg’s Test, P-value; Egger’s test, P-value) |
Effect Model |
|---|---|---|---|---|---|---|---|---|
| 2DL1 | 12 | 1933/2012 | 1866/1907 | 0.005 | 0.426 (0.233–0.777) | (0.0%; P-value = 0.944) | (Begg’s Test, 0.11; Egger’s test, 0.20) | Fixed |
| 2DL2 | 12 | 966/2012 | 843/1907 | 0.048 | 1.150 (1.001–1.323) | (84.2%; P-value < 0.001) | (Begg’s Test, 0.03; Egger’s test, 0.11) | Random |
| 2DL3 | 12 | 1879/2012 | 1774/1907 | 0.746 | 0.931 (0.605–1.432) | (0.0%; P-value = 0.51) | (Begg’s Test, 0.84; Egger’s test, 0.85) | Fixed |
| 2DL4 | 8 | 1129/1134 | 1196/1199 | 0.453 | 0.669 (0.235–1.908) | (0.0%; P-value = 0.98) | (Begg’s Test, 0.27; Egger’s test, 0.43) | Fixed |
| 2DL5 | 11 | 999/1945 | 956/1777 | 0.033 | 0.863 (0.753–0.988) | (84.7%; P-value < 0.001) | (Begg’s Test, 0.53; Egger’s test, 0.16) | Random |
| 2DS1 | 13 | 959/2287 | 873/2122 | 0.857 | 0.989 (0.873–1.120) | (48.2%; P-value = 0.026) | (Begg’s Test, 0.51; Egger’s test, 0.40) | Random |
| 2DS2 | 13 | 1063/2287 | 971/2122 | 0.784 | 0.982 (0.861–1.119) | (74.4%; P-value < 0.001) | (Begg’s Test, 0.85; Egger’s test, 0.58) | Random |
| 2DS3 | 12 | 528/2012 | 511/1907 | 0.272 | 0.912 (0.774–1.075) | (35.9%; P-value = 0.103) | (Begg’s Test, 0.99; Egger’s test, 0.82) | Fixed |
| 2DS4 | 12 | 1781/2012 | 1623/1907 | 0.126 | 1.247 (0.940–1.653) | (46.5%; P-value = 0.038) | (Begg’s Test, 0.05; Egger’s test, 0.08) | Random |
| 2DS5 | 12 | 707/2012 | 664/1907 | 0.804 | 0.983 (0.857–1.128) | (36.6%; P-value = 0.098) | (Begg’s Test, 0.63; Egger’s test, 0.94) | Fixed |
| 3DL1 | 12 | 1881/2012 | 1806/1907 | 0.584 | 1.144 (0.706–1.854) | (14.5%; P-value = 0.30) | (Begg’s Test, 0.002; Egger’s test, 0.004) | Fixed |
| 3DL2 | 8 | 1130/1134 | 1196/1199 | 0.839 | 0.9 (0.325–2.491) | (0.0%; P-value = 0.99) | (Begg’s Test, 0.90; Egger’s test, 0.29) | Fixed |
| 3DL3 | 9 | 1523/1528 | 1366/1367 | 0.945 | 0.966 (0.360–2.594) | (0.0%; P-value = 0.95) | (Begg’s Test, 0.99; Egger’s test, 0.10) | Fixed |
| 3DS1 | 13 | 964/2277 | 858/2122 | 0.553 | 1.038 (0.917–1.176) | (43.2%; P-value = 0.048) | (Begg’s Test, 0.67; Egger’s test, 0.96) | Random |
| 2DP1 | 4 | 492/497 | 594/599 | 0.769 | 0.805 (0.188–3.437) | (0.0%; P-value = 0.95) | (Begg’s Test, 0.73; Egger’s test, 0.98) | Fixed |
| 3DP1 | 3 | 248/249 | 349/349 | 0.478 | 0.542 (0.100-2.943) | (0.0%; P-value = 0.95) | (Begg’s Test, 0.29; Egger’s test, 0.38) | Fixed |
*N implies to all the T1D cases evaluated for a specific KIR gene polymorphism
*n implies to a positive state for a specific KIR gene polymorphism
Sensitivity analysis
Sensitivity analysis was carried out through the sequential exclusion of individuals of the studies. The pooled OR did not significantly deviate from sequential omission after omitting any individuals of studies, reflecting that the results were statistically robust.
Evaluation of heterogeneity test and publication bias
The factors affecting the heterogeneity among the included studies within a meta-analysis are differences in the study design, study individuals, and consequences. The heterogeneity test was carried out by Cochran’s Q test. The significant heterogeneity results were considered with (I2%>50%, PHeterogeneity<0.10). In our study, significant heterogeneity between studies were found in 2DL2 (I2 = 84.2%; P <0.001), 2DL5 (I2 = 84.7%; P < 0.001), and 2DS2 (I2 = 74.4%; P < 0.001), while the remained KIR gene polymorphisms did not exhibit heterogeneity. Accordingly, the random effects and the fixed effects model were applied to calculate the pooled ORs. Funnel plots considered as a visual method for assessing publication bias and asymmetry in this meta-analysis [40]. Five points required for analysis of publication, and other bias by Funnel plots [41]. The funnel plot represents a symmetrical inverted funnel in the absence of considerable publication bias, while publication bias results in the asymmetrical funnel plot. According to the results of by Egger’s and Begg’s tests, publication bias was observed in the meta-analyses of 3DL1 polymorphism (Begg’s Test, 0.002; Egger’s test, 0.004; Table 2). The results of KIR2DL1, KIR2DL2, and KIR2DL5 are shown in Figs. 2 and 3.
Discussion
The first investigation of the influence of genetic polymorphisms in the KIR genes on the risk of T1D was conducted in 2003 [6]. Since then, several articles have focused on identifying the association of KIRs polymorphisms with T1D proneness, but the results were controversial. To integrate the inconsistent results from the previous studies, we determined a precise protocol and performed a statistical technique. Thus, we carried out this meta-analysis, to reassess the association of KIR allelic diversity with T1D predisposition. Overall, in this meta-analysis, thirteen separate case-control studies comprising a total of 2118 healthy individuals and 2285 T1D patients were included [1, 3, 6, 23, 31–39].
Contrary to decades of studies and plentiful recent progress, the exact underlying mechanisms in T1D pathogenesis are still unclear. Both genetic and environmental elements participate in the development of T1D [42]. A thorough understanding of the immunogenetics of T1D represents an important element on the path to T1D prevention. It has been proposed that NK cells, as innate immune cells, could be involved in autoimmune diabetes [43]. In T1D, at first, the function of T effector (Teff) cells is involved in disease development and progression, but NK cells can be key elements in the development of T1D and have been indicated in the pancreas of T1D patients [44].
It seems that some HLA genes could be associated with T1D development. Nikitina-Zake et al. reported that subjects carrying specific high-risk HLA class II genes and KIR2DL2 or 2DS2 alleles might develop T1D. Moreover, those carrying alleles 5 or 5.1 of MHC-I polypeptide–related gene A (MICA) (for which an association with TID has been pointed out) in combination with KIR2DL2 or 2DS2 genes had an increased risk to have diabetes. [31]. A study performed by Jobim et al. found a protective factor for KIR2DL1 -HLA- C2 combination [39]. A study conducted by Mehres et al. revealed that children with T1D who were positive for activating KIR2DS2 and inhibitory KIR2DL2, and KIR2DL3 receptors had more often HLA-C1C1 homozygous genotypes and this association was more powerful in children diagnosed with T1D under the age of 5 years [34]. Zhi and colleagues reported that KIR/HLA combinations including KIR2DL2−/HLA-C1+; KIR2DL3+/HLA-C1+; KIR2DS2 /HLA-C1 + were positively associated with diabetes mellitus [3]. These observations emphasize the combinational role of KIR receptors and their HLA ligands in T1D risk.
On the other hand, no significant differences were reported regarding the frequency distribution of KIR genes and T1D susceptibility in the studies performed in Dutch [6], Finnish [23], Basque [32], Japanese [1], Brazilian [39]], Chinese [3], and Saudi populations [38].
The heterogeneity observed in these studies may be in part attributed to the contribution of some factors, including different demographic characteristics in different studies, geographic factors, quality of each study, various experimental outline, different genotyping methods, differences in the inclusion criteria for the control populations, and variations in the distribution of the KIR genes among populations with diverse ethnic backgrounds [45, 46]. Age at onset and gender are also associated with T1D development, therefore, it is important to select age- and gender-matched control individuals in genetic analyses [3].
There are some restrictions in the present meta-analysis. First, due to the insufficient original data, such as the environment–gene/gene-gene interaction, effect of different clinical subtypes of T1D, we could not conduct further analysis to track other risk factors. Second, we were unable to carry out subgroup analysis with respect to ethnicity because of inadequate studies. Third, only studies in the English language were included in this study. Hence, this meta-analysis may subject to publication bias. As far as we know, despite the mentioned limitations in the present study, this study concentrated on the KIR gene polymorphisms profile in susceptibility to or protection from T1D.
In conclusion, this meta-analysis indicated that 2DL1, 2DL2, and 2DL5 might be potential predisposing factors for T1D risk. Both 2DL1 and 2DL5 were associated with decreased T1D risk, while 2DL2 increased the risk of T1D. To achieve early diagnosis of T1D, KIR genes may be applied as practical biomarkers. Thus, the necessity of performing more research studies with larger sample sizes with adequate methodological quality together, more detailed and standardized data are emphasized to further obtain valid results.
Author contributions
Samaneh Soltani (SS); performed a literature search, prepared the draft of the paper, and designed the Tables.
Shayan Mostafaei (SM); analyzed data, developed the main idea, read the manuscript critically and draw the figures.
Saeed Aslani (SA); participated in manuscript preparation, and read the paper critically.
Elham Farhadi (EF); participated in manuscript drafting, and read the manuscript critically.
Mahdi Mahmoudi (MM); developed the main idea, designed the work, and read the manuscript critically.
Compliance with ethical standards
Conflict of interest
Authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Not applicable.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Shayan Mostafaei, Email:
[email protected].
Mahdi Mahmoudi, Email:
[email protected].
References
- 1.Mogami S, Hasegawa G, Nakayama I, Asano M, Hosoda H, Kadono M, et al. Killer cell immunoglobulin-like receptor genotypes in Japanese patients with type 1 diabetes. Tissue Antigens. 2007;70(6):506–10. doi: 10.1111/j.1399-0039.2007.00956.x. [DOI] [PubMed] [Google Scholar]
- 2.French AR, Yokoyama WM. Natural killer cells and autoimmunity. Arthritis Res Ther. 2003;6(1):8. doi: 10.1186/ar1034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zhi D, Sun C, Sedimbi SK, Luo F, Shen S, Sanjeevi CB. Killer cell immunoglobulin-like receptor along with HLA-C ligand genes are associated with type 1 diabetes in Chinese Han population. Diabetes Metab Res Rev. 2011;27(8):872–7. 10.1002/dmrr.1264. [DOI] [PubMed]
- 4.Sugioka DK, Goncalves CE, Bicalho MD. KIR repertory in patients with hematopoietic diseases and healthy family members. BMC Hematol. 2016;16:25. doi: 10.1186/s12878-016-0064-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ghanadi K, Shayanrad B, Ahmadi SA, Shahsavar F, Eliasy H. Colorectal cancer and the KIR genes in the human genome: A meta-analysis. Genom Data. 2016;10:118–26. doi: 10.1016/j.gdata.2016.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.van der Slik AR, Koeleman BP, Verduijn W, Bruining GJ, Roep BO, Giphart MJ. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes. 2003;52(10):2639–42. doi: 10.2337/diabetes.52.10.2639. [DOI] [PubMed] [Google Scholar]
- 7.Liang H-L, Ma S-J. Tan H-Z. Association between killer cell immunoglobulin-like receptor (KIR) polymorphisms and systemic lupus erythematosus (SLE) in populations: A PRISMA-compliant meta-analysis. Medicine. 2017;96(10). [DOI] [PMC free article] [PubMed]
- 8.Hollenbach JA, Nocedal I, Ladner MB, Single RM, Trachtenberg EA. Killer cell immunoglobulin-like receptor (KIR) gene content variation in the HGDP-CEPH populations. Immunogenetics. 2012;64(10):719–37. doi: 10.1007/s00251-012-0629-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol. 2004;173(7):4273–6. doi: 10.4049/jimmunol.173.7.4273. [DOI] [PubMed] [Google Scholar]
- 10.Suzuki Y, Hamamoto Y, Ogasawara Y, Ishikawa K, Yoshikawa Y, Sasazuki T, et al. Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol. 2004;122(5):1133–6. doi: 10.1111/j.0022-202X.2004.22517.x. [DOI] [PubMed] [Google Scholar]
- 11.Nazari M, Mahmoudi M, Rahmani F, Akhlaghi M, Beigy M, Azarian M, et al. Association of killer cell immunoglobulin- like receptor genes in iranian patients with rheumatoid arthritis. PLoS One. 2015;10(12):e0143757. doi: 10.1371/journal.pone.0143757. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE, et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 2004;50(5):1561–5. doi: 10.1002/art.20216. [DOI] [PubMed] [Google Scholar]
- 13.Kitawaki J, Xu B, Ishihara H, Fukui M, Hasegawa G, Nakamura N, et al. Association of killer cell immunoglobulin-like receptor genotypes with susceptibility to endometriosis. Am J Reprod Immunol. 2007;58(6):481–6. doi: 10.1111/j.1600-0897.2007.00533.x. [DOI] [PubMed] [Google Scholar]
- 14.Karlsen TH, Boberg KM, Olsson M, Sun JY, Senitzer D, Bergquist A, et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol. 2007;46(5):899–906. doi: 10.1016/j.jhep.2007.01.032. [DOI] [PubMed] [Google Scholar]
- 15.Erer B, Takeuchi M, Ustek D, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, et al. Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behcet’s disease. Genes Immun. 2016;17(7):396–9. doi: 10.1038/gene.2016.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Liang HL, Ma SJ, Tan HZ. Association between killer cell immunoglobulin-like receptor (KIR) polymorphisms and systemic lupus erythematosus (SLE) in populations: A PRISMA-compliant meta-analysis. Med (Baltim) 2017;96(10):e6166. doi: 10.1097/MD.0000000000006166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet. 2007;39(6):733–40. doi: 10.1038/ng2035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Mendez A, Granda H, Meenagh A, Contreras S, Zavaleta R, Mendoza MF, et al. Study of KIR genes in tuberculosis patients. Tissue Antigens. 2006;68(5):386–9. doi: 10.1111/j.1399-0039.2006.00685.x. [DOI] [PubMed] [Google Scholar]
- 19.Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia. 2004;18(12):2002–7. doi: 10.1038/sj.leu.2403525. [DOI] [PubMed] [Google Scholar]
- 20.Besson C, Roetynck S, Williams F, Orsi L, Amiel C, Lependeven C, et al. Association of killer cell immunoglobulin-like receptor genes with Hodgkin’s lymphoma in a familial study. PLoS One. 2007;2(5):e406. doi: 10.1371/journal.pone.0000406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hiby SE, Regan L, Lo W, Farrell L, Carrington M, Moffett A. Association of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage. Hum Reprod. 2008;23(4):972–6. doi: 10.1093/humrep/den011. [DOI] [PubMed] [Google Scholar]
- 22.Yan WH, Lin A, Chen BG, Zhou MY, Dai MZ, Chen XJ, et al. Possible roles of KIR2DL4 expression on uNK cells in human pregnancy. Am J Reprod Immunol. 2007;57(4):233–42. doi: 10.1111/j.1600-0897.2007.00469.x. [DOI] [PubMed] [Google Scholar]
- 23.Middleton D, Halfpenny I, Meenagh A, Williams F, Sivula J, Tuomilehto-Wolf E. Investigation of KIR gene frequencies in type 1 diabetes mellitus. Hum Immunol. 2006;67(12):986–90. doi: 10.1016/j.humimm.2006.08.295. [DOI] [PubMed] [Google Scholar]
- 24.Shastry A, Sedimbi SK, Rajalingam R, Nikitina-Zake L, Rumba I, Wigzell H, et al. Combination of KIR 2DL2 and HLA-C1 (Asn 80) confers susceptibility to type 1 diabetes in Latvians. Int J Immunogenet. 2008;35(6):439–46. doi: 10.1111/j.1744-313X.2008.00804.x. [DOI] [PubMed] [Google Scholar]
- 25.Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33(2). [DOI] [PubMed]
- 26.Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi: 10.1007/s10654-010-9491-z. [DOI] [PubMed] [Google Scholar]
- 27.Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I² index? Psychol Methods. 2006;11(2):193. doi: 10.1037/1082-989X.11.2.193. [DOI] [PubMed] [Google Scholar]
- 28.Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Akar HH, Patiroglu T, Sevinc E, Aslan D, Okdemir D, Kurtoglu S. Contribution of KIR genes, HLA class I ligands, and KIR/HLA class I ligand combinations on the genetic predisposition to celiac disease and coexisting celiac disease and type 1 diabetes mellitus. Rev Esp Enferm Dig. 2015;107(9):547–53. doi: 10.17235/reed.2015.3817/2015. [DOI] [PubMed] [Google Scholar]
- 30.Tan YY, Lin J, Huang G, Tang WL, Sedimbi SK, Sanjeevi CB, et al. Killer cell immunoglobin-like receptor and its ligand gene polymorphisms in Hunan Han patients with type 1 diabetes. Zhonghua Yi Xue Za Zhi. 2010;90(4):236–40. [PubMed] [Google Scholar]
- 31.Nikitina-Zake L, Rajalingham R, Rumba I, Sanjeevi CB. Killer cell immunoglobulin-like receptor genes in Latvian patients with type 1 diabetes mellitus and healthy controls. Ann N Y Acad Sci. 2004;1037:161–9. doi: 10.1196/annals.1337.027. [DOI] [PubMed] [Google Scholar]
- 32.Santin I, de Nanclares GP, Calvo B, Gaafar A, Castano L, Group G-N, et al. Killer cell immunoglobulin-like receptor (KIR) genes in the Basque population: association study of KIR gene contents with type 1 diabetes mellitus. Hum Immunol. 2006;67(1–2):118–24. doi: 10.1016/j.humimm.2006.02.036. [DOI] [PubMed] [Google Scholar]
- 33.van der Slik AR, Alizadeh BZ, Koeleman BP, Roep BO, Giphart MJ. Modelling KIR-HLA genotype disparities in type 1 diabetes. Tissue Antigens. 2007;69(Suppl 1):101–5. doi: 10.1111/j.1399-0039.2006.762_5.x. [DOI] [PubMed] [Google Scholar]
- 34.Mehers KL, Long AE, van der Slik AR, Aitken RJ, Nathwani V, Wong FS, et al. An increased frequency of NK cell receptor and HLA-C group 1 combinations in early-onset type 1 diabetes. Diabetologia. 2011;54(12):3062–70. doi: 10.1007/s00125-011-2299-x. [DOI] [PubMed] [Google Scholar]
- 35.Smigoc Schweiger D, Mendez A, Kunilo Jamnik S, Bratanic N, Bratina N, Battelino T, et al. Genetic risk for co-occurrence of type 1 diabetes and celiac disease is modified by HLA-C and killer immunoglobulin-like receptors. Tissue Antigens. 2014;84(5):471–8. doi: 10.1111/tan.12450. [DOI] [PubMed] [Google Scholar]
- 36.Park Y, Choi H, Park H, Park S, Yoo EK, Kim D, et al. Predominance of the group A killer Ig-like receptor haplotypes in Korean patients with T1D. Ann N Y Acad Sci. 2006;1079:240–50. doi: 10.1196/annals.1375.037. [DOI] [PubMed] [Google Scholar]
- 37.Sanjeevi S, Sun C, Kanungo A, Sanjeevi CB. Killer immunoglobulin receptor genes and their HLA-C ligand are associated with Type 1 diabetes in an Eastern Indian population. Diabet Med. 2016;33(1):91–6. doi: 10.1111/dme.12815. [DOI] [PubMed] [Google Scholar]
- 38.Osman AE, Eltayeb EN, Mubasher M, Al Harthi H, Alharbi S, Hamza MA, et al. Investigation of activating and inhibitory killer cell immunoglobulin-like receptors and their putative ligands in type 1 diabetes (T1D) Hum Immunol. 2016;77(1):110–4. doi: 10.1016/j.humimm.2015.10.019. [DOI] [PubMed] [Google Scholar]
- 39.Jobim M, Chagastelles P, Salim PH, Portela P, Wilson TJ, Curti AG, et al. Association of killer cell immunoglobulin-like receptors and human leukocyte antigen-C genotypes in South Brazilian with type 1 diabetes. Hum Immunol. 2010;71(8):799–803. doi: 10.1016/j.humimm.2010.05.014. [DOI] [PubMed] [Google Scholar]
- 40.Biljana M, Jelena M, Branislav J, Milorad R. Bias in meta-analysis and funnel plot asymmetry. Stud Health Technol Inform. 1999;68:323–8. [PubMed] [Google Scholar]
- 41.Lean IJ, Rabiee AR, Duffield TF, Dohoo IR. Invited review: Use of meta-analysis in animal health and reproduction: methods and applications. J Dairy Sci. 2009;92(8):3545–65. doi: 10.3168/jds.2009-2140. [DOI] [PubMed] [Google Scholar]
- 42.Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221–9. doi: 10.1016/S0140-6736(01)05415-0. [DOI] [PubMed] [Google Scholar]
- 43.Sun C, Sanjeevi S, Luo F, Zhi D, Sanjeevi CB. Interactions between maternal killer cell immunoglobulin receptor genes and foetal HLA ligand genes contribute to type 1 diabetes susceptibility in Han Chinese. Int J Immunogenet. 2016;43(3):125–30. doi: 10.1111/iji.12257. [DOI] [PubMed] [Google Scholar]
- 44.Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A. 2007;104(12):5115–20. doi: 10.1073/pnas.0700442104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Djulejic E, Petlichkovski A, Trajkov D, Hristomanova S, Middleton D, Spiroski M. Distribution of killer cell immunoglobulinlike receptors in the Macedonian population. Hum Immunol. 2010;71(3):281–8. doi: 10.1016/j.humimm.2009.12.001. [DOI] [PubMed] [Google Scholar]
- 46.Li X, Xia Q, Fan D, Cai G, Yang X, Wang L, et al. Association between KIR gene polymorphisms and rheumatoid arthritis susceptibility: A meta-analysis. Hum Immunol. 2015;76(8):565–70. doi: 10.1016/j.humimm.2015.06.017. [DOI] [PubMed] [Google Scholar]
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.